J Biol Chem (1986) 261:118809
Ingredients: 37% conjugated linoleic acid CLA, 14,8% green tea extract, soybean oil, 7,4% L-carnitine, capsule (gelatine, glycerin, water, colour: E172) Purpose The product is designed for pro-active persons and sportsmen
Limitations: - CT-388 data is early stage (Phase 1/2), making comparisons to late-stage or approved competitors regarding efficacy somewhat premature.- Competitor trials involving semaglutide and tirzepatide are based on larger patient populations and longer duration, providing a more robust data set validating their therapeutic benefit.- Weight loss achieved with GLP-1 receptor agonists such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide appear greater than the weight loss observed to date with CT-388.- Competitor agents have established cardiovascular benefits and substantial net weight reductions, which set a high efficacy bar for CT-388 to meet or exceed.- Incretin therapies are challenged by supply shortages and complex titration schemes
So read on, learn, ask questions, and be safe
